drugset / Trial / NCT01346085

Calcineurin Inhibitor (CNI)-Free Immunosuppressive Regimen in T1D Patients Receiving Islet Transplantation

NCT01346085

NaSingle-groupOpen-labelTreatment

Summary

Our final objective is to develop an adoptive therapy with tolerogenic donor-specific Tr1 cells in T1D patients undergoing pancreatic islet transplantation (Tx). The achievement of this objective depends by the availability of an immunosuppressive treatment (IS) compatible with the survival, function, and expansion of the transferred Tr1 cells. For this purpose the investigators design a CNI-free single-group, phase 1-2 trial excluding the ATG or anti-CD25 induction therapy after the 1st islet infusion

Timeline

Start
2006-10
Primary completion
2009-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic 1.5 mg/kg
Background Methylprednisolone Other / unclassified 500 mg
Background Mycophenolate Mofetil Small molecule 2 g
Background Prednisone Other / unclassified 10 mg
Background Sirolimus Small molecule 0.1 mg/kg